These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31412004)

  • 1. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.
    Grivas P; Lalani AA; Pond GR; Nagy RJ; Faltas B; Agarwal N; Gupta SV; Drakaki A; Vaishampayan UN; Wang J; Barata PC; Gopalakrishnan D; Naik G; McGregor BA; Kiedrowski LA; Lanman RB; Sonpavde GP
    Eur Urol Oncol; 2020 Oct; 3(5):695-699. PubMed ID: 31412004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
    Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
    Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis.
    Liu H; Chen J; Huang Y; Zhang Y; Ni Y; Xu N; Zhao F; Tang Y; Liu H; Sun G; Shen P; Liu Z; Huang J; Liao B; Zeng H
    Int J Surg; 2024 Jun; 110(6):3923-3936. PubMed ID: 38573063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.
    Kaseb AO; Sánchez NS; Sen S; Kelley RK; Tan B; Bocobo AG; Lim KH; Abdel-Wahab R; Uemura M; Pestana RC; Qiao W; Xiao L; Morris J; Amin HM; Hassan MM; Rashid A; Banks KC; Lanman RB; Talasaz A; Mills-Shaw KR; George B; Haque A; Raghav KPS; Wolff RA; Yao JC; Meric-Bernstam F; Ikeda S; Kurzrock R
    Clin Cancer Res; 2019 Oct; 25(20):6107-6118. PubMed ID: 31363003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder.
    Rink M; Schwarzenbach H; Riethdorf S; Soave A
    World J Urol; 2019 Sep; 37(9):1785-1799. PubMed ID: 30367205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
    Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
    Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival.
    Alessandrino F; Williams K; Nassar AH; Gujrathi R; Silverman SG; Sonpavde G; Shinagare AB
    Radiology; 2020 Jun; 295(3):572-580. PubMed ID: 32228295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.
    Vandekerkhove G; Todenhöfer T; Annala M; Struss WJ; Wong A; Beja K; Ritch E; Brahmbhatt S; Volik SV; Hennenlotter J; Nykter M; Chi KN; North S; Stenzl A; Collins CC; Eigl BJ; Black PC; Wyatt AW
    Clin Cancer Res; 2017 Nov; 23(21):6487-6497. PubMed ID: 28760909
    [No Abstract]   [Full Text] [Related]  

  • 13. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
    Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
    Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
    Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
    Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
    Ravi P; Ravi A; Riaz IB; Freeman D; Curran C; Mantia C; McGregor BA; Kilbridge KL; Pan CX; Pek M; Choudhury Y; Tan MH; Sonpavde GP
    Oncologist; 2022 May; 27(5):e406-e409. PubMed ID: 35294031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
    Yin M; Grivas P; Wang QE; Mortazavi A; Emamekhoo H; Holder SL; Drabick JJ; Woo MS; Pal S; Vasekar M; Folefac E; Clinton SK; Monk P; Joshi M
    Oncologist; 2020 Aug; 25(8):680-688. PubMed ID: 32275806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.
    Takemura K; Fukushima H; Ito M; Kataoka M; Nakanishi Y; Sakamoto K; Suzuki H; Tobisu KI; Koga F
    Urol Oncol; 2019 Feb; 37(2):108-115. PubMed ID: 30478012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
    Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.